Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review.

Mehmet BaysalMeltem BayrakAhmet Emre Eskazan

Published in: Expert review of hematology (2023)

Ease of management and patient comfort should be regarded as benefits of DOACs compared to VKAs. However, it would be appropriate to bring an individualized approach until we obtain high-quality data with prospectively designed studies involving more patients and longer follow-up time concerning the use of DOACs in patients with MPNs.

Keyphrases

direct oral anticoagulants
venous thromboembolism
atrial fibrillation
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
electronic health record
case report
low grade
big data
patient reported outcomes
artificial intelligence
patient reported
high grade